(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of -2.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Ideaya Biosciences's revenue in 2026 is $234,127,000.On average, 17 Wall Street analysts forecast IDYA's revenue for 2026 to be $3,757,589,975, with the lowest IDYA revenue forecast at $1,418,395,415, and the highest IDYA revenue forecast at $8,662,343,426. On average, 16 Wall Street analysts forecast IDYA's revenue for 2027 to be $11,956,011,962, with the lowest IDYA revenue forecast at $5,673,581,659, and the highest IDYA revenue forecast at $17,398,983,755.
In 2028, IDYA is forecast to generate $21,368,561,127 in revenue, with the lowest revenue forecast at $11,111,728,977 and the highest revenue forecast at $41,683,457,088.